TML-TRA-19

TML-TRA-19 is a preclinical-stage antimalarial candidate being developed by Themis Medicare. It utilizes a Novel Drug Delivery System (NDDS) to achieve a long-acting formulation, intended to improve treatment outcomes or provide sustained prophylaxis against malaria. While the specific active pharmaceutical ingredient (API) and its molecular target are not publicly disclosed in the company's pipeline, the "TRA" designation in the code name is often associated with trioxolane or artemisinin-related antimalarial compounds. The development focuses on leveraging advanced formulation technology to extend the drug's half-life and therapeutic window.

Other names

TML-TRA-19-Themis Medicare-NDDS-Long Acting Anti-malarialTML-TRA19-Themis Medicare-NDDS-Long Acting Anti-malarialTML-TRA 19-Themis Medicare-NDDS-Long Acting Anti-malarial